MDX 11

Drug Profile

MDX 11

Alternative Names: Anti-AML/SCCL-trigger monoclonal antibody; Anti-CD15 monoclonal antibody PM-81; Monoclonal antibody PM-81

Latest Information Update: 20 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 20 Aug 2002 Discontinued - Phase-II for Acute myeloid leukaemia in USA (unspecified route)
  • 20 Oct 1997 Phase-II clinical trials for Acute myeloid leukaemia in USA (Unknown route)
  • 01 Oct 1996 A study has been added to the therapeutic trials, adverse effects, immunogenicity and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top